CN110590795B - 一类多并杂环螺羟吲哚类化合物的合成方法 - Google Patents

一类多并杂环螺羟吲哚类化合物的合成方法 Download PDF

Info

Publication number
CN110590795B
CN110590795B CN201910959305.8A CN201910959305A CN110590795B CN 110590795 B CN110590795 B CN 110590795B CN 201910959305 A CN201910959305 A CN 201910959305A CN 110590795 B CN110590795 B CN 110590795B
Authority
CN
China
Prior art keywords
ddd
nmr
compound
cdcl
polyatomic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910959305.8A
Other languages
English (en)
Other versions
CN110590795A (zh
Inventor
任海
潘卫东
宋俊蓉
李志遥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Original Assignee
Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences filed Critical Key Laboratory of Natural Product Chemistry of Guizhou Academy of Sciences
Priority to CN201910959305.8A priority Critical patent/CN110590795B/zh
Publication of CN110590795A publication Critical patent/CN110590795A/zh
Application granted granted Critical
Publication of CN110590795B publication Critical patent/CN110590795B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一类多并杂环螺羟吲哚类化合物的合成方法。该类化合物在有机溶剂中，在绿色环保、廉价的铁催化剂作用下一步反应得到。得到的部分化合物是临床二期开发药物NITD609及其类似物或者重要的药物中间体。同时本发明的制备方法反应收率高，催化剂绿色环保，催化剂用量少，水是唯一副产物，绿色无污染，适用取代基范围广，操作简单，有望实现工业化应用前景。

Description

一类多并杂环螺羟吲哚类化合物的合成方法
技术领域
本发明属于药物及药物中间体的生成工艺领域，尤其涉及一类多并杂环螺羟吲哚类化合物的合成方法。
背景技术
多并杂环螺羟吲哚作为一类重要的核心结构单元，广泛地存在于天然产物和众多具有生物活性分子中(a)Peddibhotla,S.Curr.Bioact.Compd.2009,5,20.(b)Trost,B.M.；Brennan,M.K.Synthesis 2009,2009,3003.(c)Christensen,M.K.；Erichsen,K.D.；Trojel-Hansen,C.；Tjornelund,J.；Nielsen,S.J.；Frydenvang,K.；Johansen,T.N.；Nielsen,B.；Sehested,M.；Jensen,P.B.；Ikaunieks,M.；Zaichenko,A.；Loza,E.；Kalvinsh,I.；Bjorkling,F.J.Med.Chem.2010,53,7140.(d)Sharma,I.；Tan,D.S.Nat.Chem.2013,5,157.(e)Cao,Z.-Y.；Zhou,F.；Zhou,J.Acc.Chem.Res.2018,51,1443.如何高效构多并杂环螺羟吲哚结构衍生物一直是有机合成领域的研究热点难点。
2010年Diagana等人在Top期刊Science上报道了四氢-β-咔啉螺羟吲哚分子NITD609(式1)，数据表明该分子具有优异的抗疟活性(IC50＝0.9nM)。更值得注意的是，该分子不同于现有抗疟药物美氟喹(mefloquine)和青蒿素(artemisinin)的作用机制，其通过调节P型ATP酶(PfATP4)从而迅速抑制寄生虫中蛋白质的合成。该研究为当前抗疟药物严峻的耐药性问题提供一条全新的缓解途径。目前诺华公司正在对其开展临床Ⅱ期试验研究。2014年,McLeod等人发现化合物NITD609除具有抗疟原虫活性外，对弓形虫速殖子也表现出较好的药理活性，在体外细胞实验中其IC 50值为1μM。此外该化合物安全性高，即使用药量在大于10μM，对人体正常细胞也无损害。(a)Rottmann,M.；McNamara,C.；Yeung,B.K.；Lee,M.C.；Zou,B.；Russell,B.；Seitz,P.；Plouffe,D.M.；Dharia,N.V.；Tan,J.；Cohen,S.B.；Spencer,K.R.；Gonzalez-Paez,G.E.；Lakshminarayana,S.B.；Goh,A.；Suwanarusk,R.；Jegla,T.；Schmitt,E.K.；Beck,H.P.；Brun,R.；Nosten,F.；Renia,L.；Dartois,V.；Keller,T.H.；Fidock,D.A.；Winzeler,E.A.；Diagana,T.T.Science 2010,329,1175.
Figure GDA0002821636490000021
式1：抗疟疾药物分子NITD609
由于极具应用价值和前景。以NITD609母核四氢-β-咔啉螺羟吲哚骨架结构的合成为例，科学家进行了大量的研究并取得了系列重要的研究成果(a)Zheng,H.；Liu,X.；Xu,C.；Xia,Y.；Lin,L.；Feng,X.Angew.Chem.Int.Ed.2015,54,10958.(b)Yeung,B.K.S.；Zou,B.；Rottmann,M.；Lakshminarayana,S.B.；Ang,S.H.；Leong,S.Y.；Tan,J.；Wong,J.；Keller-Maerki,S.；Fischli,C.；Goh,A.；Schmitt,E.K.；Krastel,P.；Francotte,E.；Kuhen,K.；Plouffe,D.；Henson,K.；Wagner,T.；Winzeler,E.A.；Petersen,F.；Brun,R.；Dartois,V.；Diagana,T.T.；Keller,T.H.J.Med.Chem.2010,53,5155.(c)冯小明，郑海丰，刘小华，林丽丽.中国专利：CN104926813A。一直以来，通过文献调研，发现含有氧杂环螺羟吲哚和硫杂环螺羟吲哚等结构单元、且与四氢-β-咔啉螺羟吲哚母核相对应的螺环结构衍生物一直未见报道(式2)。值得一提的是，通过已报道的策略和方法都无法实现对该类结构的合成。
Figure GDA0002821636490000022
式2：抗疟疾药物分子类似结构
综上所述，本领域尚缺乏一种反应操作简便、合成步骤短、适用取代基范围广、能工业化系统合成包括NITD609母核在内的多种类型的并杂环螺羟吲哚的合成方法，该现状亟待解决。
发明内容
本发明意在提供一种多类型多并杂环螺羟吲哚的合成方法，以解决现有技术合成方法中反应产物类型单一，底物兼容性有限，以及催化剂昂贵等问题。
众所周知，自然界铁资源丰富，不仅如此，铁也是人体微量元素之一。铁催化具有廉价、安全和环保等显著优点，比如FeCl3是一种常用的污水废水处理剂。将铁催化剂运用于具有药理活性化合物的高效构建并实现其工业化生产具有重要的价值和意义。
本发明提供的一种多并杂环螺羟吲哚的合成方法，于惰性溶剂中，在微量的铁盐催化下，将式1化合物与式2化合物进行反应，从而形成式A化合物，化学式如下：
Figure GDA0002821636490000031
上述各式中，R1、R2、R3和R4各自独立的为H、取代或未取代的C1-C15的烷基、卤素、取代或未取代的C6-C15芳基、烷氧基或苄氧基；
R5为H、取代或未取代的C1-C15的烷基，取代或未取代的C6-C15芳基，酰基；
R6和R7各自独立的为H、取代或未取代的C1-C15的烷基、卤素、取代或未取代的C6-C15芳基、烷氧基或苄氧基或连接关环形成结构式B的多环体系，其中R10、R11、R12和R13各自独立的为H、取代或未取代的C1-C15的烷基、卤素、取代或未取代的C6-C15芳基、烷氧基或苄氧基。
Figure GDA0002821636490000032
R8、R9各自独立的为H、取代或未取代的C1-C15的烷基、卤素、烷氧基或苄氧基；
X、Y各自独立的为O，S，NR14，其中R14为H、取代或未取代的C1-C15的烷基，取代或未取代的C6-C15芳基，酰基；
式1化合物和2化合物的摩尔比例为1:1-1:1.5；
优选的，催化剂铁盐为FeCl3，Fe(ClO4)3.6H2O，Fe(OTf)3，FeCl2；
优选的，催化剂铁盐的用量为0.01％—1％；
优选的，反应温度在25℃-60℃下进行，进一步优选的，所述的反应温度在30℃-50℃下进行。
优选的，惰性溶剂选自，N,N-二甲基酰胺、二甲基亚砜、四氢呋喃或其组合。
本发明的工作原理：本发明的发明人通过长期深入系统的研究，发现了一种全新的多并杂环螺羟吲哚的合成方法，于惰性溶剂中，在微量铁盐的催化下，将式1化合物与式2化合物进行反应，从而得到结构多样的多并杂环螺羟吲哚类化合物。该方法具有原料简单，易得，催化剂绿色环保，底物适用范围广，操作简便，反应效率高，水是唯一副产物，绿色少污染等优点。在此基础上，发明人完成了本发明。本发明制得的多并杂环螺羟吲哚类化合物在抗疟疾、抗菌等生物医药领域有着十分重要的应用前景。
具体实施方式
下面结合具体实施，进一步阐明本发明。应理解，这些实施例仅用于说明本发明而不限制与本发明的范围。下列实施例子中为注明具体条件的实验方法，通常按照常规条件，或按照制造商所建议的条件，若未注明反应温度，均表示该反应在室温条件下进行。除非另有说明，否则百分比和份数胺重量计算。
以下实施例子中均采用本领域常规的后处理方法进行纯化。
实施例1
实施例1将1-1(2mmol)，2-1(2mmol)，FeCl3(0.02mmol)加入到25mL反应管中，抽换氮气，在氮气保护下加入5mL四氢呋喃，随后升至40℃搅拌28h，TLC跟踪至原料2-1消失。制得产物A-1，产率为90％。
Figure GDA0002821636490000041
制备得到的A-1的核磁共振(1H NMR和13C NMR)、红外和高分辨质谱检测数据为：
white solid,28h,574.0mg,90％yield.1H NMR(600MHz,CDCl3)δ7.59(d,J＝8.0Hz,1H),7.39(td,J＝7.8,1.0Hz,1H),7.23-7.10(m,4H),7.05(t,J＝7.6Hz,1H),6.93(d,J＝8.0Hz,1H),4.74-4.70(m,1H),4.23-4.19(m,1H),3.30(s,3H),3.17-3.10(m,1H),3.03(s,3H),3.00-2.97(m,1H).13C NMR(150MHz,CDCl3)δ174.2,144.0,137.6,130.8,130.1,128.7,126.2,125.5,123.5,122.2,119.2,118.6,111.2,108.9,108.7,76.1,62.2,29.4,26.4,22.0.IR(KBr):2917.7,2838.7,2360.3,1716.5,1610.2,1469.3,1369.0,1299.8,1242.0,1181.9,10153.3,1096.2,1048.39,996.31.HRMS-ESI:Exact masscalcd.for C20H18N2O2Na+[M+Na]+:341.1260；Found:341.1263.
2-20的具体实施方式，参考实施例1，部分代表性化合物的核磁共振(1H NMR和13CNMR)、红外和高分辨质谱检测数据如下：
实施例2：
Figure GDA0002821636490000051
A-2yellow solid,12h,515mg,95％yield.1H NMR(600MHz,CDCl3)δ7.39(td,J＝7.8,1.2Hz,1H),7.24-7.20(m,2H),7.08(td,J＝7.8,1.2Hz,1H),6.90(dd,J＝8.4,6.6Hz,2H),4.94(ddd,J＝11.4,10.2,3.6Hz,1H),4.18(ddd,J＝11.4,5.4,2.4Hz,1H),3.24(s,3H),3.08(ddd,J＝16.2,10.2,5.4Hz,1H),2.86(ddd,J＝16.2,3.6,2.4Hz,1H).13C NMR(150MHz,CDCl3)δ175.2,143.6,136.2,131.7,131.1,130.5,127.0,125.1,124.7,123.4,108.5,61.4,26.4,25.6.IR(KBr):2953.2,2359.6,1725.3,1610.9,1492.4,1468.9,1346.3,1224.5,1103.4,1049.9,990.7.HRMS-ESI:Exact mass calcd.for C15H13NO2SNa+[M+Na]+:294.0565；Found:294.0557.
实施例3：
Figure GDA0002821636490000061
A-3yellow solid,12h,391mg,65％yield.1H NMR(600MHz,CDCl3)δ7.58(d,J＝2.7Hz,2H),7.39(td,J＝7.8,0.9Hz,1H),7.20(d,J＝7.2Hz,1H),7.14-7.09(m,3H),7.06(t,J＝7.5Hz,1H),6.94(d,J＝7.8Hz,1H),3.89-3.79(m,1H),3.34(dt,J＝13.1,5.4Hz,1H),3.25(s,3H),2.98(t,J＝5.7Hz,2H).13C NMR(150MHz,DMSO)δ176.6,143.5,136.1,131.4,130.0,129.8,127.1,124.6,123.3,122.4,119.5,118.4,112.4,111.0,108.7,61.4,39.9,26.5,22.0.IR(KBr):3450.5,2938.1,1715.2,1610.6,1469.8,1369.9,1346.0,1236.2,1088.4,751.7,538.3.HRMS-ESI:Exact mass calcd.for HRMS-ESI:Exactmasscalcd.for C19H18N3O+[M+H]+:304.1444；Found:304.1444.
实施例4：
Figure GDA0002821636490000062
A-4yellow solid,23h,224mg,37％yield.1H NMR(600MHz,DMSO)δ10.75(s,1H),8.49(s,1H),7.54(d,J＝7.8Hz,1H),7.48(d,J＝8.0Hz,1H),7.26-7.22(m,3H),7.16-7.10(m,2H),7.09-7.06(m,1H),3.81(d,J＝20.8Hz,1H),3.71(d,J＝20.8Hz,1H),3.26(s,3H).13C NMR(150MHz,DMSO)δ173.9,169.5,143.8,137.2,130.0,129.9,127.4,125.4,124.3,122.9,122.1,118.9,118.3,111.3,109.4,106.7,62.7,28.5,26.7.IR(KBr):3244.0,2923.8,2359.8,1703.1,1612.9,1660.6,1468.2,1367.0,1227.1,1084.9,1055.8.
HRMS-ESI:Exact mass calcd.for HRMS-ESI:Exact mass calcd.for C19H16N3O2 +[M+H]+:318.1243；Found:318.1231.
实施例5：
Figure GDA0002821636490000071
A-5yellow solid,15h,191mg,35％yield.1H NMR(600MHz,CDCl3)δ7.59(d,J＝7.8Hz,1H),7.39(td,J＝7.8,1.2Hz,1H),7.25-7.19(m,2H),7.17-7.11(m,2H),7.08(td,J＝7.2,0.8Hz,1H),6.96(d,J＝7.8Hz,1H),3.90(ddd,J＝13.6,11.4,3.6Hz,1H),3.40-3.36(m,1H),3.35(s,3H),3.28(ddd,J＝15.6,11.4,4.8Hz,1H),2.95(s,3H),2.91(ddd,J＝13.6,4.6,3.0Hz,1H).13C NMR(150MHz,CDCl3)δ176.1,143.0,136.8,129.7,129.3,126.8,124.9,123.4,122.5,119.1,118.4,114.5,108.7,108.7,70.3,47.6,29.9,26.8,25.4,24.0.I R(KBr):3441.9,2900.3,2923.5,2360.4,1702.5,1606.6,1491.8,1472.9,1342.3,1366.0,1239.7,1084.9,1126.0.HRMS-ESI:Exact mass calcd.for C20H21N2OS+[M+H]+:335.1218；Found:335.1252.
实施例6：
Figure GDA0002821636490000072
A-6yellow solid,22h,227mg,74％yield.1H NMR(600MHz,CDCl3)δ7.56(dd,J＝8.0,5.0Hz,1H),7.38(d,J＝7.8Hz,1H),7.33(dd,J＝7.8,5.2Hz,1H),7.24(dd,J＝6.6,3.0Hz,2H),7.18(d,J＝7.2Hz,1H),7.06(d,J＝7.2Hz,1H),6.91(d,J＝7.8Hz,1H),4.91-4.87(m,1H),4.26(ddd,J＝11.4,5.4,2.4Hz,1H),3.26(s,3H),3.13(ddd,J＝15.6,9.6,5.4Hz,1H),2.94-2.89(m,1H).13C NMR(150MHz,CDCl3)δ173.9,154.9,148.0,144.4,130.9,127.5,127.3,125.1,124.5,123.3,122.9,119.3,114.8,111.6,108.8,75.9,62.1,26.5,21.9.IR(KBr):3430.9,2966.1,2931.2,2360.4,2341.1,1722.9,1599.3,1493.0,1461.1,1356.5,1289.3,1235.6,1025.9.HRMS-ESI:Exact mass calcd.for C19H15NO3Na+[M+Na]+:328.0944；Found:328.0944.
实施例7：
Figure GDA0002821636490000081
A-7yellow solid,22h,305mg,48％yield.1H NMR(600MHz,CDCl3)δ7.73(t,J＝8.0Hz,2H),7.43(td,J＝8.0,3.6Hz,2H),7.36-7.33(m,1H),7.25(dd,J＝7.2,0.6Hz,1H),7.10(td,J＝7.8,0.6Hz,1H),6.93(d,J＝7.8Hz,1H),5.08(ddd,J＝11.2,10.2,3.6Hz,1H),4.34(ddd,J＝11.4,6.0,2.4Hz,1H),3.27(s,3H),3.20(ddd,J＝10.2,7.8,3.6Hz,1H),3.05(ddd,J＝15.6,3.6,2.4Hz,1H).13C NMR(150MHz,CDCl3)δ173.9,154.9,148.0,144.4,130.9,127.5,127.3,125.1,124.5,123.3,122.8,119.2,114.7,111.6,108.8,75.9,62.1,26.4,21.9.IR(KBr):3401.8,2927.0,2360.1,1709.8,1612.2,1494.7,1469.3,1345.2,1238.5,1157.1,1095.0,1044.0,1017.9,986.0,924.2.HRMS-ESI:Exactmass calcd.forC19H15NO2SNa+[M+Na]+:344.0718；Found:344.0718.
实施例8：
Figure GDA0002821636490000091
A-8yellow solid,23h,406.1mg,61％yield.1H NMR(600MHz,CDCl3)δ7.58(d,J＝7.8Hz,1H),7.19(ddd,J＝13.8,10.2,4.2Hz,2H),7.13-7.10(m,1H),7.05(d,J＝8.0Hz,1H),6.50(dd,J＝10.8,2.4Hz,2H),4.70(ddd,J＝11.2,9.2,4.0Hz,1H),4.19(ddd,J＝11.1,5.0,3.6Hz,1H),3.83(s,3H),3.26(s,3H),3.11(ddd,J＝14.4,9.0,5.4Hz,1H),3.04(s,3H),2.97(dt,J＝15.6,3.6Hz,1H).13C NMR(150MHz,CDCl3)δ174.7,162.1,145.4,137.5,130.3,126.3,126.1,122.0,120.5,119.1,118.5,111.0,108.8,106.8,96.9,75.8,62.1,55.6,29.3,26.4,22.0.IR(KBr):2934.3,2883.0,2359.3,1726.1,1618.1,1621.0,1419.4,1349.6,1245.8,1103.9,995.1.HRMS-ESI:Exact mass calcd.for C21H20N2O2Na+[M+Na]+:355.1417；Found:355.1416.
实施例9：
Figure GDA0002821636490000092
A-9yellow solid,17h,604.1mg,87％yield.1H NMR(600MHz,CDCl3)δ7.60(d,J＝7.8Hz,1H),7.24-7.18(m,2H),7.16-7.10(m,1H),6.92(s,1H),6.79(s,1H),4.73(ddd,J＝11.2,9.8,3.8Hz,1H),4.21(ddd,J＝11.1,5.2,3.0Hz,1H),3.55(s,3H),3.16(ddd,J＝15.2,8.9,4.0Hz,1H),3.07(s,3H),2.97(dt,J＝15.5,3.4Hz,1H),2.58(s,3H),2.19(s,3H).13C NMR(150MHz,CDCl3)δ175.0,139.1,137.5,134.9,133.1,130.6,129.3,126.1,124.1,122.0,120.0,119.2,118.65,111.0,108.9,75.5,62.1,29.8,29.4,22.1,20.6,18.8.IR(KBr):2915.7,2364.3,1713.8,1463.5,1342.3,1039.38,1104.7,1078.4.HRMS-ESI:Exact mass calcd.for C22H22N2O2Na+[M+Na]+:369.1579；Found:369.1570.
实施例10：
Figure GDA0002821636490000101
A-10yellow solid,23h,627.5mg,90％yield.1H NMR(600MHz,CDCl3)δ7.63(d,J＝7.8Hz,1H),7.26-7.21(m,2H),7.18-7.15(m,1H),7.11(t,J＝9.0Hz,1H),6.56(dd,J＝10.8,2.4Hz,2H),4.77-4.73(m,1H),4.25-4.22(m,1H),3.88(s,3H),3.31(s,3H),3.19-3.14(m,1H),3.09(s,3H),3.02(dt,J＝15.0,3.6Hz,1H).13C NMR(150MHz,CDCl 3)δ174.7,162.1,145.4,137.5,130.3,126.3,126.1,122.0,120.4,119.1,118.5,111.1,108.8,106.8,96.9,75.8,62.1,55.6,29.3,26.4,22.0.IR(KBr):2923.8,2360.2,1723.8,1608.0,1453.3,1354.4,1107.0,1054.1,993.2.HRMS-ESI:Exact mass calcd.forC21H20N2O3Na+[M+Na]+:371.1366；Found:371.1366.
实施例11：
Figure GDA0002821636490000102
A-11yellow solid,16h,398mg,59％yield.1H NMR(600MHz,CDCl3)δ7.59(d,J＝7.8Hz,1H),7.24-7.21(m,1H),7.19(d,J＝8.4Hz,1H),7.13(dd,J＝10.8,3.6Hz,1H),7.10(td,J＝8.8,2.4Hz,1H),6.92(dd,J＝7.2,2.4Hz,1H),6.86(dd,J＝8.8,3.6Hz,1H),4.71(ddd,J＝11.2,9.4,3.6Hz,1H),4.21(ddd,J＝11.2,5.4,3.4Hz,1H),3.29(s,3H),3.14(ddd,J＝14.8,9.6,5.2Hz,1H),3.06(s,3H),2.99(dt,J＝15.5,3.6Hz,1H).19F NMR(565MHz,CDCl3)δ118.9.13C NMR(150MHz,CDCl3)δ174.0,160.4,158.8,139.9(d,J＝2.0Hz),137.6,130.3(d,J＝7.6Hz),129.4,126.0,122.4,119.4,118.6,117.0(d,J＝23.6Hz),113.6(d,J＝24.9Hz),111.4,108.9(d,J＝7.9Hz),76.1,62.3,29.4,26.7,22.0.IR(KBr):3045.0,2913.9,2852.2,2358.5,1711.3,1494.4,1265.0,1103.1,1047.9.HRMS-ESI:Exact mass calcd.for C20H17N2O2FNa+[M+Na]+:359.116；Found:359.1166.
实施例12：
Figure GDA0002821636490000111
A-12yellow solid,18h,460.5mg,65％yield.1H NMR(600MHz,CDCl3)δ7.63(d,J＝7.8Hz,1H),7.35(t,J＝8.0Hz,1H),7.26-7.22(m,2H),7.18-7.14(m,1H),7.03(d,J＝8.4Hz,1H),6.85(d,J＝7.8Hz,1H),4.82(td,J＝11.2,3.6Hz,1H),4.30(ddd,J＝11.4,5.4,1.2Hz,1H),3.31(s,3H),3.23(ddd,J＝16.2,11.4,5.4Hz,1H),3.12(s,3H),3.00-2.94(m,1H).13C NMR(150MHz,CDCl3)δ173.7,145.8,147.5,132.8,131.8,128.2,126.0,125.3,124.7,122.1,119.2,118.6,112.2,108.9,107.0,76.0,62.5,29.3,26.6,21.8.IR(KBr):34223.0,2960.2,2925.2,2854.1,2359.5,1719.7,1610.5,1460.5,13445.4,1261.7,1122.9,997.3,938.0.HRMS-ESI:Exact mass calcd.for C20H18N2O2Cl[M+H]+:353.1051；Found:353.1049.
实施例13：
Figure GDA0002821636490000121
A-13yellow solid,18h,633.3mg,90％yield.1H NMR(600MHz,CDCl3)δ7.60(d,J＝7.8Hz,1H),7.37(dd,J＝8.4,2.4Hz,1H),7.23-7.19(m,2H),7.15(dd,J＝6.6,1.8Hz,2H),6.86(d,J＝8.4Hz,1H),4.69(ddd,J＝11.4,9.6,4.0Hz,1H),4.21(ddd,J＝11.2,5.2,3.4Hz,1H),3.29(s,3H),3.14(ddd,J＝14.7,9.2,5.2Hz,1H),3.06(s,3H),2.99(dt,J＝15.5,3.7Hz,1H).13C NMR(150MHz,CDCl 3)δ173.9,142.5,137.6,130.7,130.4,129.3,129.1,126.0,125.9,122.4,119.4,118.7,111.5,109.7,109.0,75.9,62.4,29.5,26.7,22.0.IR(KBr):3425.6,2924.6,1719.6,1612.8,1493.0,1468.5,1375.2,1337.7,1261.3,1182.9,1101.2,1044.1.HRMS-ESI:Exact mass calcd.for C20H17N2O2ClNa+[M+Na]+:375.0871；Found:375.0872.
实施例14：
Figure GDA0002821636490000122
A-14yellow solid,22h,540mg,76％yield.1H NMR(600MHz,CDCl 3)δ7.59(d,J＝7.8Hz,1H),7.31(dd,J＝8.4,1.2Hz,1H),7.23-7.18(m,2H),7.15-7.12(m,1H),7.03(dd,J＝7.2,1.2Hz,1H),6.95(t,J＝7.8Hz,1H),4.69(ddd,J＝11.4,9.6,3.6Hz,1H),4.19(ddd,J＝11.4,5.4,3.0Hz,1H),3.66(s,3H),3.16-3.11(m,1H),3.07(s,3H),2.97(dt,J＝15.6,3.6Hz,1H).13C NMR(150MHz,CDCl3)δ174.5,140.0,137.6,133.0,131.4,129.5,126.0,124.3,124.1,122.4,119.3,118.6,116.1,111.4,109.8,75.4,62.2,39.9,29.5,22.0.IR(KBr):3423.0,2923.2,2840.6,2360.0,1721.0,1608.7,1459.5,1356.7,1111.6,1056.8,963.3,944.6.HRMS-ESI:E xact mass calcd.for C20H17N2O2ClNa+[M+Na]+:375.0871；Found:375.0870.
实施例15：
Figure GDA0002821636490000131
A-15yellow solid,48h,475.2mg,60％yield.1H NMR(600MHz,CDCl3)δ7.72(dd,J＝8.4,1.8Hz,1H),7.60(d,J＝7.8Hz,1H),7.43(d,J＝1.8Hz,1H),7.25-7.19(m,2H),7.16-7.13(m,1H),6.72(d,J＝8.2Hz,1H),4.68(ddd,J＝11.2,9.0,4.2Hz,1H),4.20(ddd,J＝11.2,5.4,3.6Hz,1H),3.28(s,3H),3.14(ddd,J＝14.4,9.6,5.4Hz,1H),3.06(s,3H),2.99(dt,J＝15.6,3.6Hz,1H).13C NMR(150MHz,CDCl3)δ173.6,143.7,139.6,137.6,134.1,130.9,129.3,126.0,122.4,119.4,118.7,111.5,110.7,109.0,85.9,62.3,29.5,26.5,22.0.IR(K Br):2924.4,2360.5,1719.9,1606.9,1455.6,1375.7,1253.1,1180.8,1112.6,1049.1,995.0,939.2.HRMS-ESI:Exact mass calcd.for C20H17N2O2BrNa+[M+Na]+:419.0363；Found:419.0363.
实施例16:
Figure GDA0002821636490000132
A-16yellow solid,48h,42.3mg,53％yield.1H NMR(600MHz,CDCl3)δ7.60(d,J＝7.8Hz,1H),7.52(dd,J＝8.4,1.8Hz,1H),7.27(d,J＝1.8Hz,1H),7.24-7.18(m,2H),7.15-7.12(m,1H),6.81(d,J＝8.4Hz,1H),4.68(ddd,J＝11.2,9.3,3.9Hz,1H),4.20(ddd,J＝11.2,5.4,3.6Hz,1H),3.28(s,3H),3.16-3.11(m,1H),3.06(s,3H),2.99(dt,J＝15.5,3.6Hz,1H).13C NMR(150MHz,CDCl3)δ173.7,143.0,137.6,133.6,129.3,128.6,122.4,119.4,118.7,116.2,111.5,110.5,110.1,109.0,75.9,62.4,29.5,26.5,22.0.IR(KBr):3442.0,2932.8,2360.7,1720.5,1609.4,1344.1,1102.3,1046.9.HRMS-ESI:Exactmasscalcd.for C20H17N2O2BrNa+[M+Na]+:419.0363；Found:419.0363.
实施例17：
Figure GDA0002821636490000141
A-17yellow solid,13h,646.0mg,81％yield.1H NMR(600MHz,CDCl3)δ7.59(d,J＝7.8Hz,1H),7.42(s,1H),7.23-7.17(m,3H),7.15-7.11(m,1H),7.09(d,J＝1.8Hz,1H),7.01(d,J＝7.8Hz,1H),4.68(ddd,J＝11.2,9.0,3.6Hz,1H),4.19(ddd,J＝11.2,5.4,3.4Hz,1H),3.28(s,3H),3.12(ddd,J＝14.4,9.6,5.2Hz,1H),3.05(s,3H),2.98(dt,J＝15.5,3.6Hz,1H).13C NMR(150MHz,CDCl 3)δ174.1,145.3,137.6,129.4,127.6,126.7,126.3,126.1,124.6,122.4,119.4,118.6,112.3,111.4,109.0,75.6,62.3,29.5,26.5,22.0.IR(KBr):3426.8,2941.6,2358.5,1723.0,1607.8,1494.4,1469.6,1364.0,1240.2,1099.9,1058.6,991.3,939.4.HRMS-ESI:Exact mass calcd.for C20H17N2O2BrNa+[M+Na]+:419.0366；Found:419.0364.
实施例18：
Figure GDA0002821636490000151
A-18yellow solid,18h,483mg,61％yield.1H NMR(600MHz,CDCl3)δ7.59(d,J＝7.8Hz,1H),7.49(dd,J＝8.4,0.6Hz,1H),7.20(dd,J＝18.0,7.8Hz,2H),7.13(t,J＝7.2Hz,1H),7.06(d,J＝7.2Hz,1H),6.88(t,J＝7.8Hz,1H),4.69(td,J＝10.2,3.8Hz,1H),4.19(ddd,J＝11.0,5.0,2.4Hz,1H),3.67(s,3H),3.14(ddd,J＝15.0,9.6,5.2Hz,1H),3.06(s,3H),2.97(dt,J＝15.6,3.4Hz,1H).13C NMR(150MHz,CDCl3)δ174.7,141.3,137.6,136.3,131.7,129.5,126.0,124.6,122.4,119.3,118.6,111.4,108.9,102.8,75.3,62.2,30.0,29.5,22.0.IR(K Br):2923.8,2848.3,2360.2,2341.2,1723.8,1608.0,1580.6,1453.3,1354.4,1107.0,1054.6,993.2,944.2.HRMS-ESI:Exact mass calcd.for C20H18N2O2Br+[M+H]+:397.0552；Found:397.0544.
实施例19：
Figure GDA0002821636490000152
A-19yellow solid,19h,618mg,71％yield.1H NMR(600MHz,CDCl3)δ7.72(dd,J＝8.2,1.6Hz,1H),7.60(d,J＝7.9Hz,1H),7.43(d,J＝1.6Hz,1H),7.24-7.19(m,2H),7.16-7.13(m,1H),6.71(d,J＝8.2Hz,1H),4.68(ddd,J＝11.3,9.4,4.0Hz,1H),4.20(ddd,J＝11.1,5.1,3.4Hz,1H),3.28(s,3H),3.17-3.12(m,1H),3.06(s,3H),2.99(dt,J＝15.5,3.6Hz,1H).13C NMR(150MHz,CDCl3)δ173.6,143.7,139.6,137.6,134.1,130.9,129.4,126.0,122.4,119.4,118.7,111.5,110.7,109.0,85.9,75.7,62.4,29.5,26.5,22.0.IR(KBr):3422.2,2912.8,2360.0,2339.2,1720.6,1605.8,1465.4,1343.0,1242.2,1103.0,1049.3.H RMS-ESI:Exact mass calcd.for C20H17N2O2INa+[M+Na]+:467.0227；Found:467.0230.
实施例20：
Figure GDA0002821636490000161
A-20yellow solid,23h,574mg,73％yield.1H NMR(600MHz,CDCl3)δ8.94(s,1H),7.61(d,J＝7.8Hz,1H),7.28(dd,J＝7.8,1.2Hz,1H),7.21(dd,J＝12.8,4.2Hz,2H),7.14(dd,J＝10.4,4.0Hz,2H),7.01(t,J＝7.2Hz,1H),6.92(d,J＝7.8Hz,1H),4.71(ddd,J＝11.4,8.8,4.2Hz,1H),4.25(dt,J＝11.4,4.6Hz,1H),3.17-3.12(m,4H),3.03(dd,J＝11.4,4.2Hz,1H).13C NMR(150MHz,CDCl3)δ176.8,141.1,137.6,130.8,129.8,129.1,126.1,125.7,123.5,122.3,119.3,118.6,111.2,110.8,109.1,62.2,29.7,29.4,22.0.IR(KBr):3214.4,2954.4,2923.8,2853.0,2360.2,2339.2,1727.0,1618.5,1471.1,1374.4,1208.2,1181.4,1058.1,993.1,933.0.HRMS-ESI:Exact mass calcd.for C19H17N2O2 +[M+H]+:305.1290；Found:305.1282.
实施例21：
Figure GDA0002821636490000162
A-21yellow solid,23h,580mg,87％yield.1H NMR(600MHz,CDCl3)δ7.47(d,J＝8.4Hz,1H),7.38(td,J＝7.8,1.2Hz,1H),7.14(dd,J＝7.2,0.6Hz,1H),7.04(td,J＝7.8,0.6Hz,1H),6.96(d,J＝7.2Hz,2H),6.92(d,J＝7.8Hz,1H),4.70(ddd,J＝11.2,9.2,3.6Hz,1H),4.20(ddd,J＝11.2,5.4,3.6Hz,1H),3.30(s,3H),3.11(ddd,J＝14.6,9.0,5.4Hz,1H),2.99(s,3H),2.98-2.94(m,1H),2.46(s,3H).13C NMR(150MHz,CDCl3)δ174.3,144.0,138.0,132.0,130.7,129.4,128.8,125.4,124.0,123.5,120.9,118.2,111.0,108.9,108.6,62.2,29.3,26.4,22.1,21.9.IR(KBr):3406.9,2916.3,2846.4,1714.4,1609.8,1470.2,1365.0,1345.8,1243.7,1096.2,1046.5,995.2,948.3.HRMS-ESI:Exactmass calcd.forC21H20N2O2Na+[M+Na]+:355.1417；Found:355.1414.
实施例22：
Figure GDA0002821636490000171
A-22yellow solid,23h,54.0mg,81％yield.1H NMR(600MHz,CDCl3)δ7.50(d,J＝8.6Hz,1H),7.42(td,J＝7.8,1.2Hz,1H),7.17(dd,J＝7.3,0.7Hz,1H),7.07(td,J＝7.6,0.7Hz,1H),6.99(d,J＝7.2Hz,2H),6.95(d,J＝7.8Hz,1H),4.74(ddd,J＝11.1,9.2,4.0Hz,1H),4.24(ddd,J＝11.1,5.1,3.5Hz,1H),3.33(s,3H),3.15(ddd,J＝14.6,9.1,5.2Hz,1H),3.02(s,3H),3.02-2.98(m,1H),2.50(s,3H).13C NMR(150MHz,CDCl3)δ174.3,144.0,138.0,132.0,130.7,129.4,128.8,125.4,124.0,123.5,120.9,118.2,111.0,108.9,108.6,76.1,62.2,29.3,26.4,22.1,21.9.IR(KBr):3416.5,2928.3,2854.1,2259.4,1712.7,1611.8,1468.3,1344.0,1096.7,1042.2,935.1.HRMS-ESI:Exact masscalcd.for C21H20N2O2Na+[M+Na]+:355.1417；Found:355.1416.
实施例23：
Figure GDA0002821636490000181
A-23yellow solid,23h,775mg,98％yield.1H NMR(600MHz,CDCl3)δ7.72-7.66(m,1H),7.37(dd,J＝11.4,4.2Hz,1H),7.23-7.09(m,7H),6.99(t,J＝7.8Hz,1H),6.82(d,J＝7.8Hz,1H),6.67-6.62(m,2H),4.98-4.85(m,2H),4.39(d,J＝18.0Hz,1H),4.25(ddd,J＝11.4,5.4,2.4Hz,1H),3.27(ddd,J＝15.6,10.2,5.4Hz,1H),3.14-3.01(m,1H),2.80(s,3H).13C NMR(150MHz,CDCl3)δ173.5,144.1,137.8,136.7,130.8,129.8,128.2,128.0,127.0,126.3,125.4,125.3,123.3,122.6,119.6,118.6,111.9,109.4,108.4,75.8,61.7,46.6,25.7,22.0.IR(KBr):3438.4,2806.2,2874.8,2360.1,1732.3,1609.0,1489.0,1465.7,1344.8,1241.2,1175.4,1090.1,1054.2,994.4,929.8.HRMS-ESI:Exactmasscalcd.for C26H22N2O2Na+[M+Na]+:417.1573；Found:417.1574.
本领域技术人员可对本发明做各种改动或修改，这些等价形式同样落于本申请所附权利要求书所限定的范围。应理解，本发明范围中，本发明的上述各技术特征和在下文(如实施例)中具体描述的各种技术特征之间都可以互相组合，从而构成新的或优选的技术方案。

Claims (2)

1.一类多并杂环螺羟吲哚类化合物的合成方法，其特征在于：以四氢呋喃作为溶剂，在催化量的铁盐FeCl3的催化下，将化合物1与化合物2进行反应，从而形成化合物A：
Figure FDA0002821636480000011
所述化合物A的结构为
Figure FDA0002821636480000012
反应式中化合物1和化合物2的摩尔比例为1:1，催化剂铁盐的用量为1％。
2.根据权利要求1所述的多并杂环螺羟吲哚类化合物的合成方法，其特征在于，反应温度为25-60℃。
CN201910959305.8A 2019-10-10 2019-10-10 一类多并杂环螺羟吲哚类化合物的合成方法 Active CN110590795B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910959305.8A CN110590795B (zh) 2019-10-10 2019-10-10 一类多并杂环螺羟吲哚类化合物的合成方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910959305.8A CN110590795B (zh) 2019-10-10 2019-10-10 一类多并杂环螺羟吲哚类化合物的合成方法

Publications (2)

Publication Number Publication Date
CN110590795A CN110590795A (zh) 2019-12-20
CN110590795B true CN110590795B (zh) 2021-01-22

Family

ID=68866266

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910959305.8A Active CN110590795B (zh) 2019-10-10 2019-10-10 一类多并杂环螺羟吲哚类化合物的合成方法

Country Status (1)

Country Link
CN (1) CN110590795B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114907254B (zh) * 2021-12-15 2023-07-25 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种3-碳环螺羟吲哚类化合物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1231660A (zh) * 1996-09-27 1999-10-13 赫彻斯特马里恩鲁斯公司 用于四氢异喹啉及相关杂环化合物合成的Pictest－Spengler反应
WO2009132921A1 (en) * 2008-04-29 2009-11-05 Novartis Ag Spiro-indole derivatives for the treatment of parasitic diseases
CN104230942A (zh) * 2014-08-19 2014-12-24 华东师范大学 一种螺[吡咯啉基-3,2’-氧化吲哚]衍生物及其合成方法和应用
CN105693719A (zh) * 2016-01-15 2016-06-22 南阳师范学院 一种3,3-螺环吲哚酮类化合物的合成方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1231660A (zh) * 1996-09-27 1999-10-13 赫彻斯特马里恩鲁斯公司 用于四氢异喹啉及相关杂环化合物合成的Pictest－Spengler反应
WO2009132921A1 (en) * 2008-04-29 2009-11-05 Novartis Ag Spiro-indole derivatives for the treatment of parasitic diseases
CN104230942A (zh) * 2014-08-19 2014-12-24 华东师范大学 一种螺[吡咯啉基-3,2’-氧化吲哚]衍生物及其合成方法和应用
CN105693719A (zh) * 2016-01-15 2016-06-22 南阳师范学院 一种3,3-螺环吲哚酮类化合物的合成方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A Compact Approach to an Isomeric Iheyamine A System and X-ray Crystal Structure of 5-Methyl-5H-azepino[2,3-b:4,5-b"]diindole;John B.Bremner et al.;《Synthetic Communications》;20081231;第38卷;第1931-1939页 *
B.B.Semenov et al..Diastereoselective synthesis of 1,1-disubstituted 4-phenyl-2,3,4,9-tetrahydrospiro-β-carbolines from β-phenyltryptamine and isatin derivatives.《Russian Chemical Bulletin, International Edition》.2005,第54卷(第4期),第988-991页. *
Catalytic Stereoselective Synthesis of Diverse Oxindoles and Spirooxindoles from Isatins;Jacob P. MacDonald et al.;《ACS Comb.Sci.》;20120326;第14卷;第285-293页 *
Enantioselective Pictet–Spengler reactions of isatins for the synthesis of spiroindolones;Joseph J. Badillo et al.;《Tetrahedron Letters》;20110824;第52卷;第5550-5553页 *
Synthesis of isochromans via Fe(OTf)2-catalyzed Oxa-PicteteSpengler cyclization;Jimei Zhou et al.;《Tetrahedron》;20181017;第74卷;第7040-7046页 *

Also Published As

Publication number Publication date
CN110590795A (zh) 2019-12-20

Similar Documents

Publication Publication Date Title
CN109020911B (zh) 用于制备bictegravir的中间体及其制备方法
CN105732622A (zh) 一种阿哌沙班的制备方法
CN110590795B (zh) 一类多并杂环螺羟吲哚类化合物的合成方法
CN108863890B (zh) 一种4-吡咯啉-2-酮衍生物及其制备方法
CN108456238A (zh) 奥贝胆酸衍生物及奥贝胆酸的制备方法
CN111233745B (zh) （e）1-（9-烷基-咔唑-3-）-丙烯酸及其制备方法
CN101151256B (zh) 二苯并*庚因衍生物的制造方法
CN106045902A (zh) 一种3‑溴‑6‑甲基‑2‑吡啶甲醛的制备方法
CN109678862B (zh) 一种多取代二苯乙烯基吲哚衍生物的制备方法
US20030088094A1 (en) Novel synthesis and crystallization of piperazine ring-containing compounds
CN110563721A (zh) 一种新的盐酸阿扎司琼的制备方法
CN104059063A (zh) 7,7-二氟-4,5,6,7-四氢吡唑并[4,3-c]吡啶及其衍生物的制备方法
CN115028597B (zh) 一种tempo连续脱氢环化制备苯并恶唑类衍生物的方法和应用
CN110204456B (zh) 多取代萘衍生物及其合成方法
CN112521298B (zh) 一种利多卡因的合成方法
CN110981838B (zh) 5-亚胺-四氢呋喃基甲胺衍生物及其制备方法和应用
CN110669030B (zh) 一种异苯并呋喃双酯类衍生物及其合成方法
CN108863750B (zh) 一种2-丁烯-1,4-二酮类化合物的合成方法
CN102267973B (zh) 青蒿素中间体、合成方法和用途
CN106831522A (zh) 内酰胺类化合物及其制备方法
CN104151278B (zh) 1-苯基-2,3-萘二羧酸酐及其衍生物的合成方法
CN106008419B (zh) 一种季酮酸的合成工艺
CN115433097A (zh) 一种无金属制备4-丁氧基苯甲酸(2-二乙胺基乙基)酯的方法
KR100486316B1 (ko) 5,11-디히드로-6에이치-디벤즈[비,이]아제핀-6-온의새로운 제조방법
CN111592545A (zh) 一种二氢吡咯并[1,2-a]吲哚衍生物及其合成方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant